IsoRay (ISR) Issues Quarterly Earnings Results, Misses Estimates By $0.01 EPS
IsoRay (NYSEAMERICAN:ISR) issued its quarterly earnings data on Thursday. The healthcare company reported ($0.03) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.02) by ($0.01), Bloomberg Earnings reports. The company had revenue of $1.54 million during the quarter. IsoRay had a negative net margin of 127.66% and a negative return on equity of 62.92%.
Shares of IsoRay (ISR) traded down $0.01 during midday trading on Friday, reaching $0.47. 125,269 shares of the company’s stock traded hands, compared to its average volume of 158,235. IsoRay has a 1 year low of $0.38 and a 1 year high of $0.69. The firm has a market cap of $25.35, a PE ratio of -4.27 and a beta of 1.11.
Separately, Maxim Group set a $3.00 price objective on shares of IsoRay and gave the company a “buy” rating in a research note on Wednesday, November 15th.
IsoRay, Inc is a medical technology company. The Company, through its subsidiary, IsoRay Medical, Inc, develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. The Company is engaged in the production and sales of Cesium-131 (Cs-131) brachytherapy seeds.
Receive News & Ratings for IsoRay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IsoRay and related companies with MarketBeat.com's FREE daily email newsletter.